Avadel Announces New Positive Data for Once-at-Bedtime FT218 for Narcolepsy and Once-Nightly Dosing Preference Among Patients and Clinicians
DUBLIN, Ireland, March 11, 2022. Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced new data will be presented in eight posters at the World Sleep 2022 congress in Rome.... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 11, 2022 Category: Pharmaceuticals Source Type: clinical trials
A Study to Assess the Long-term Efficacy and Safety of AXS-12 (Reboxetine) in Subjects With Narcolepsy
Conditions: Narcolepsy; Cataplexy; Excessive Daytime Sleepiness Interventions: Drug: AXS-12 (reboxetine); Drug: Placebo Sponsor: Axsome Therapeutics, Inc. Enrolling by invitation (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 9, 2021 Category: Research Source Type: clinical trials
